U.S. Stocks Rise on Vaccine Rollout, Stimulus Hopes - WSJ
Updated Dec. 14, 2020 9:37 am ET
Listen to this article
4 minutes
This feature is powered by text-to-speech technology. Want to see it on more articles?
Give your feedback below or email audiofeedback@wsj.com.
U.S. stocks rose Monday on optimism that talks for additional fiscal stimulus are progressing and that the rollout of Covid-19 vaccines could help stem the pandemic.
The Dow Jones Industrial Average climbed 220 points, or 0.7%, shortly after the opening bell. The S&P 500 added 0.6% and the Nasdaq Composite rose 0.8%.
U.S. lawmakers on Sunday signaled a growing willingness to compromise on the most contentious issues that have held up the passage of a fresh coronavirus-relief package in recent months. Leadership from both parties indicated they might look to passing a narrower spending bill. Investors are betting that a deal will be struck, and the additional spending will help bolster the economic rebound.
Covid-19 Vaccinations in the U.S. Set to Roll Out Monday
0:00 / 3:52
Covid-19 Vaccinations in the U.S. Set to Roll Out Monday
Covid-19 Vaccinations in the U.S. Set to Roll Out Monday
Pfizer has packed Covid-19 vaccines onto trucks and started deliveries in the U.S. as the first vaccinations are set to begin Monday. WSJ explains how America’s most urgent vaccination campaign in decades is rolling out. Photo: Morry Gash/pool/Shutterstock
“In the U.S., it is all about fiscal policy,” said Justin Onuekwusi, head of retail multiasset funds at Legal & General Investment Management. “The markets have priced some of this in and believe it is going to happen.”
Pfizer started shipping its Covid-19 vaccine in the U.S., dispatching trucks from a Michigan plant. Inoculations could begin as soon as Monday. That is bolstering optimism that rising infection levels may be checked in coming months, prompting an end to restrictions on social and business activity. An end to lockdowns would improve the outlook for companies whose operations have been disrupted this year by the pandemic.
The vaccine “gives you greater certainty around the earnings numbers for 2021 and 2022 because there is a lesser probability of lockdowns,” Mr. Onuekwusi said. “The longer you spend at lower earnings levels, the more companies start to get into trouble because demand isn’t there, and then you get this permanent economic scaring.”
Shares of Alexion Pharmaceuticals ALXN 30.30% rose 29% after AstraZeneca agreed to buy the Boston-based company for $39 billion in cash and stock. Shares in AstraZeneca fell 7%.
Inoculations with a Covid-19 vaccine from Pfizer and partner BioNTech could begin around the U.S. as early as Monday.
Photo: Pascal Bonniere/Zuma Press
Shares of vaccine makers rose after the U.S. Food and Drug Administration authorized Pfizer and partner BioNTech SE’s shot on Friday. Pfizer edged up 0.1%, Moderna gained 3.4% and Novavax climbed 4.8%.
Pluralsight rose 5.7% after private-equity firm Vista Equity Partners agreed to buy the educational-software maker.
In bond markets, the yield on the 10-year U.S. Treasury note ticked up to 0.925%, from 0.892% on Friday. Yields rise when bond prices fall.
Overseas, the pan-continental Stoxx Europe 600 rose 0.8%.
The British pound rose 1.1% against the dollar. Investors are hopeful that the U.K. and the European Union will strike a trade deal after both sides agreed to continue negotiations past a Sunday deadline. Officials said they were narrowing differences over some of the issues that have bedeviled the talks.
“The fact that the talks are continuing has left a spark of hope that both sides do want to find compromise,” said Jane Foley, head of foreign-exchange strategy at Rabobank.
Trading in Asia ended on a mixed note. China’s Shanghai Composite Index advanced 0.7% and Japan’s Nikkei 225 edged 0.3% higher. South Korea’s Kospi declined 0.3%.